Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70490 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Audrey Fresse und 3 weiteren Autor:innen. Beteiligte Einrichtung: Regional Pharmacovigilance Center of Nancy, Pharmaco-toxicology Department, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Colitis. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature.
Methods
To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and disproportionality analysis of ocrelizumab‐induced colitis registered in VigiBase, as well as an extensive literature review and a description of two cases from Luxembourg reported to our pharmacovigilance centre.
Results
Our VigiBase analysis revealed 400 cases of ocrelizumab‐induced colitis, with 79.0% serious cases and a median time to onset of 17 months. The preferred term (PT) coded was ‘colitis’ (53.0%), followed by PTs related to inflammatory bowel diseases (33.5%). Significant disproportionality was found for high‐level term ‘colitis’ and for ‘colitis’, ‘colitis microscopic’ and ‘immune‐mediated enterocolitis’ PTs. Our literature review revealed 24 case reports corresponding to 36 patients with a median time to onset of 18 months and a predominance of unspecified colitis (61.1%) and inflammatory bowel diseases (27.8%). Two patients relapsed after ocrelizumab resumption.
Conclusions
Together, our findings of two relevant clinical cases of ocrelizumab‐induced colitis, the literature review and the significant VigiBase disproportionality, suggest a potential safety signal for ocrelizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regional Pharmacovigilance Center of Nancy, Pharmaco-toxicology Department, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France.
- Department of Gastroenterology, Centre Hospitalier Emile Mayrisch, Esch sur Alzette, Luxembourg.
- Department of Neurology, Centre Hospitalier Luxembourg, Luxembourg-Ville, Luxembourg.
ORCID-Profile: Audrey Fresse
Zitieren
APA
Fresse, A., Hommel, C., Petitpain, N., & Kerschen, P. (2026). Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70490
Vancouver
Fresse A, Hommel C, Petitpain N, Kerschen P. Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70490
BibTeX
@article{Fresse2026,
author = {Fresse, Audrey and Hommel, Christophe and Petitpain, Nadine and Kerschen, Philippe},
title = {Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70490}
}
EUVIMED